GeneGrafts LTD is a biotechnology company developing proprietary technology for modulating excitable tissues (e.g. Brain, Heart) by cell therapy. This new paradigm can be used for the treatment of various diseases focusing on Parkinsons disease but also for other neurological disorders, and cardiac arrhythmias.

GeneGrafts is based in Haifa, Israel. The company has raised seed funding from the Office of the Chief Scientist of the Israeli Ministry of Industry and Trade, 4 major Venture Capital funds and a large international strategic partner, and began operations in November 2003. The company was also funded by the 6th European Framework Program under the project Photolysis.